FXS4640
/ Fosun Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 21, 2025
XS-03-II201: XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
(clinicaltrials.gov)
- P1/2 | N=102 | Not yet recruiting | Sponsor: NovaOnco Therapeutics Co., Ltd.
New P1/2 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF
September 04, 2025
XS-03-II201: XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
(clinicaltrials.gov)
- P1/2 | N=102 | Enrolling by invitation | Sponsor: NovaOnco Therapeutics Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Colorectal Cancer • Oncology • Solid Tumor • BRAF
1 to 2
Of
2
Go to page
1